`
`® 0 European Patent Office
`Office européen des brevets
`
`@) Publicationnumber:
`
`0 214 779
`Al
`
`@
`
`EUROPEAN PATENT APPLICATION
`
`@ Application number: 86306326.9
`
`@) Date of filing: 15.08.86
`
`@® mci: C 07 D 313/12
`C 07 C 59/86,
`C 07 C 65/36,
`C 07 C 65/38,
`C 07 C 99/00,
`C 07 C 101/28,
`C 07 C 101/42,
`C 07 C 121/78,
`A 61 K 31/335, A 61 K 31/19
`
`Date of publication of application:
`18.03.87 Bulletin
`87/12
`
`@) Designated ContractingStates:
`AT BE CH DE FR GB IT LI NL SE
`
`@
`
`Inventor: Lever, William O., Jr.
`338, Grandview Road
`Skillman New Jersey 28558 (US)
`
`Leighton, Harry Jefferson
`1904, White Plains Road
`Chapel Hill North Carolina 27514 (GB)
`
`
`
`
`
`@
`® Priority: 17.08.85 GB 8520662
`Applicant: THE WELLCOME FOUNDATIONLIMITED
`183-193 Euston Road
`
`Lendon NW1 2BP (GB)
`
`
`
`
`
`Representative: Rollins, Anthony Johnet al
`Group Patents & Agreements The Wellcome Foundation
`Ltd Langley Court
`Beckenham Kent BRA3 3BS (GB)
`
`@) Tricyclic compounds.
`@ The present invention provides a compound of formula (I}
`
`8 9™N.
`
`10
`
`CH(CH,)_NR“R®
`en
`
`is -CHa-CHe-.
`or a salt, ester or amide thereof: wherein R!
`CH2-O- or -O-CH2-: R?2 and R3 are the sameor different and are
`each hydrogen. C1-4 alkyl or taken together with the nitrogen
`comprise a nitrogen-containing heterocyclic ring having four to
`six ring members; R4 is a single bond or a C1.7 bivalent aliphatic
`hydrocarbon group may be joined to the aromatic ring system
`at the 2, 3. 8 or 9 positions: n is 0 to 3. processes forits
`preparation and intermediates therefor, pharmaceutical compo-
`sitions containing it and its use in medicine.
`
`EP0214779Al
`
`Bundesdruckerei Berlin
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 1
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 1
`
`
`
`Description
`
`0214 779
`
`Tricyclic Compounds
`
`The present invention relates to new chemical compounds which have potent antihistaminic activity, to
`processes for preparing them andto their use in medicine. Belg. Patent 623259, Neth. Patent Appl. 6407758,
`Neth. Patent Appl. 6411861 and Belg. Patent 641498 disclose a group of 11-[(dialkylamino)alkylidene]-6,
`11-dihydrodibenz[b,e]oxepins as psychotherapeutic agents the most outstanding of whichis the compound
`named, (11-(3-(dimethylamino) propylidene)-6, 11-dihydrodibenz[b.e]oxepin), and hereinafter referred to byits
`generic name, doxepin. Doxepin has been acceptedas an antidepressant in humanclinical chemotherapy and
`an antipruritic for veterinary use. We have now discovered that a group of carboxylic acid derivatives of
`doxepin possess surprisingly potentantihistaminic and antiasthmatic properties. {n this invention, compound
`(2Z)-11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid exhibits extremely
`good antihistaminic activity in vivo.
`Accordingly this invention provides a compound of the formula (1),
`
`
`
`CH(CH.),NR2R3
`
`(I)
`
`is -CHe-CHe-, -CH2-O- or -O-CH2-;
`or a salt. ester or amide thereof; wherein R'
`R2 and R3 are the sameordifferent and are each hydrogen, C1-4 alkyl or taken together with the nitrogen
`comprise a nitrogen-containing heterocyclic ring having four to six ring members:
`Ré is a single bond or a Cy.7 bivalent aliphatic hydrocarbon group and may be joined to the aromatic ring
`system at the 2, 3, 8 or 9 positions. n is 0 to 3.
`Of the compounds of formula (I) those of formula (ll), wherein R1 is as defined herein above. and R5is a
`single bond or -CH=CH-, are preferred.
`
`R!
`
`R5CO2H
`
`CH(CH2)2N(CH3)2
`
`(II)
`
`The most preferred compoundsof formula (Il), are those of formula (Ha) and formula(IIb) wherein R§ is as
`defined for formula {Il}
`
`0OCG Gr
`
`CH(CH2)2N(CH3)2
`
`CH(CH2)2N(CH3)2
`
`(IIA)
`
`(UB)
`
`Examples of compounds of formula (HA) include:
`(1) (2)-11-(3-(Dimethylamino) propylidene)-6. 11-dihydrodibenz[b,e]oxepin-2-carboxylic acid
`(2} (E)-11-(3-(Dimethylamino) propylidene)-6, 11-dihydrodibenz[b,e]oxepin-2-carboxylic acid
`(3} (E)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydrodibenz[b.e]oxepin-3-carboxylic acid
`(4) (2)-11-(3-(Dimethylamino) propylidene)-6, 11-dihydrodibenz[b,e]oxepin-3-carboxylic acid
`(5) (E)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydrodibenz[b,e]oxepin-8-carboxylic acid
`(6) (2-1 1-(3-(Dimethylamino) propylidene)-6, 11-dihydrodibenz[b,e]oxepin-8-carboxylic acid
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 2
`
`10
`
`15
`
`20
`
`2
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 2
`
`
`
`0214779
`
`(Z)-5-(3-(Dimethylamino)propylidene)-10, 11-dihydro-5H-dibenzo[a,a]cyclohepten-3-carboxylic
`
`(7) (E)-11-(3-(Dimethylamino) propylidene)-6, 11-dihydrodibenz[b,e]oxepin-9-carboxylic acid
`(8) (Z)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydrodibenz[b, e]oxepin-9-carboxylic acid
`(9) (E)-11-(3-(Dimethylamino) propylidene)-6, 11-dihydrodibenz[b.e]oxepin-2-acrylic acid
`(10) (Z)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydrodibenz[b.e]oxepin-2-acrylic acid
`Examples of compounds of formula (118) include
`(11)
`(£)-5-(3-(Dimethylamino)propylidene)-10, 11-dihydro-5H-dibenzo[a,a]cyclohepten-3-carboxylic
`acid
`(12)
`acid
`The compoundsof the present invention exist in either the cis (Z) or trans (E) isomers (in relation to the
`bridge oxygen in the case of formula (IIA) and the acid side chain in the case of formula (IIB)).
`If the
`compoundsof formula (!) or(I!) contain a double bondin the acid bearing side chain, i.e. R4 or RS, there exists
`a second possibility of Z and E isomeric forms. All such geometric isomers and the isomeric mixture of these
`compoundsare included within the scope of the present invention. Salts, amides and esters of the compounds
`of the formula (I) and (If) are included within the scope of the invention. While esters and amides of the
`compoundsof the formulae(I) and (Il) have antihistamineactivity in their own right, they may also be useful
`intermediates in the preparation of the carboxy compoundsof the formulae (I) and(il). Amides derived from
`ammonia, primary amines or amino acids, such as glycine, are particularly suitable. Suitable esters include
`conventional ester groups knownto be usefu! for protecting carboxylic acid groups such as C1.¢ alkyi esters
`wherein the alkyl group is straight or branched chain and is optionally substituted by halogen. Alkyl esters
`(C1-4) are particularly preferred.
`Solvates of the compoundsof the formulae (I) and (Il) are also included within the scope of the present
`invention. Preferred solvates include hydrates and Cy.4 alkanolates.
`Salts of the compoundsof formula (1) may be either acid addition salts or salts formed with the carboxylic
`acid group. Acid addition salts are preferred but salts formed from the carboxylic acid group may be
`particularly useful in preparing the corresponding carboxy compound. Whenusedin medicine. the salts of the
`compoundsof formulae(I) and (II) should be both pharmacologically and pharmaceutically acceptable, but
`non pharmaceutically acceptable salts may conveniently be used to prepare the free active compound or
`pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention. Such
`pharmacologically and pharmaceutically acceptable acid addition salts include, but are not limited to, those
`prepared from the following acids: hydrochloric, sulphuric, nitric, phosphoric, maleic, salicylic, toluene-p-sul-
`phonic, tartaric, citric, methanesulphonic, formic, malonic, isethionic, succinic, naphthalene-2-suiphonic and
`benzenesulphonic. Also, pharmaceutically acceptable salts can be prepared as ammonium salts. alkaline
`metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
`The present invention also provides analogous methods for preparing compounds of formula (I), for
`example:
`a) (i) A compoundof formula (1) may be prepared via the well known Wittig method (e.g., U.S. Patents
`3,354,155 and 3,509,175) by reaction of a compound of formula (Ill).
`
`R!
`
`R4CO2H
`
`(11)
`
`The Wittig reagent, Ph3P =CH(CHa)nNRaRs; /e., formula (IV), is conveniently
`(CeHs)3P = CH(CHa)nNR2R3 (IV)
`prepared by reacting a compound of the formula Phg3PCH2(CH2)nNReRsBr, with a strong base. such as
`sodium hydride or Ci.6 alkyl
`lithium in a suitable inert
`solvent,
`such as tetrahydrofuran or
`dimethoxyethane at or near room temperature. tt will be appreciated by thoseskilled in the art of organic
`chemistry that protection of the carboxy group may be desirable or required prior to the Wittig reaction
`and deprotection after the reaction.
`(ii) A compound of formuia (lt) also may be prepared via the well known Grignard conditions (e.g.,
`Belg. 623,259) in which a Grignard reagent, i.e. (R2AS3NCH2CH2CH2Mg X where X is a halogen atom,
`reacted with a compound of formula (Hl), followed by dehydration with a strong acid.
`b) A compound of formula (I) wherein R4 is a single bond can be prepared by carboxylation of a
`compound of formula (V)
`
`10
`
`18
`
`25
`
`45
`
`60
`
`65
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 3
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 3
`
`
`
`0 214 779
`
`CH(CH2),NR2R3
`
`(V)
`
`10
`
`15
`
`20
`
`25
`
`30
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`wherein R1, R2, R3 and n are as defined, vide supra and X is a hydrogen or halogen atom (suitably a
`bromine or chloride atom attacheddirectly to the ring system in the 2, 3, 8 or 9 positions. For example. a
`compound of formula (V) can be treated with a metalating agent such as butyllithium followed by a
`reaction with carbon dioxide. When X is hydrogen separation of isomers may be required to obtain the
`desired compound of formula(I). When X is a halogen atom, a compound of formula (V) can be reacted
`with magnesium in an appropriate solvent followed by reaction with carbon dioxide via the Grignard
`procedure (The Merck Index, ninth ed., page ONR-38, Merck and Co., Rahway, NJ. (1976).
`c) A compound of formula (I) wherein R4 is other than a single bond can be synthesized by reacting a
`compound of formula (V) (wherein X is a halogen atom) with a compound of formula (VI),
`CH2 = CH-R§-COR? (VI)
`wherein R® is a C1-5 bivalent aliphatic hydrocarbon and R? is a removable carboxylic acid protecting
`group such as one derived from a reaction of the carboxylic acid group which has been activated (e.g.
`converted to an acyl chloride) with an alcohol or amine. In some cases this reaction may need to be
`facilitated by a palladium catalyst (v. Org. Chem.42, 3903-3907 (1977)). A variation of this method involves
`a reaction of a compound of formula (VII) with a compound of formula Vi in a similar manner, vide supra,
`followed by catalytic reduction of the double bond in the carboxylic bearing side chain that followed by the
`Wittig reaction described in Section a) (i) or(ii), vide supra. The carboxylic acid groups may then be
`regenerated by deprotection if required.
`d) When the preparation of a compound of the formula (I) wherein R4 is CH=CHis required, a
`compound of the formula (VII)
`
`R!
`
`0
`
`( VII)
`
`wherein R? is as defined, vide supra and X is halogen can be reacted with acrylic acid or an acrylic acid
`ester, with useof a catalyst if needed, by a method analogousto that described in b), vide supra,followed
`by a Wittig reaction as describedin parta)(i) or(ii), vide supra. The carboxylic acid can be regenerated by
`deprotection if desired.
`A compoundof formula (VII) may be prepared by reacting a compound of formula (VIII).
`
`R!
`
`CO2H
`
`( VIIT)
`
`wherein R1 and X are as defined, vide supra with a dehydrating agent such as (CF3CO)20/BF3*OEta.
`(e) It is possible to convert one compoundof the formula(II) to another compoundof the formula (I!l}
`by methods well knownto thoseskilled in the art, for example the reduction of one or more double bonds
`or de-esterification of an ester group or hydrolysis of an amide, followed by a Wittig reaction with
`Ph3P = CHa(CH2)nNRaR3 as described, vide supra.
`(f} A compound of formula (VIII) can be converted to a Grignard reagent or an organolithium reagent by
`methods well known ito those skilled in the art (after protecting the CO2H group) then reacted with
`dimethyl formamide to obtain the corresponding aldehyde. Such an aldehyde can be convertedto an acid
`by oxidation or reaction with a trialkyl phosphonium acetate or an equivalent. By methods well knownin
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 4
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 4
`
`
`
`0214779
`
`the art of organic chemistry, after deprotecting such an acid can be dehydrated as described in d), vide
`supra to give a compound of formula (Ill).
`(g) A compound of the formula (V) where X is halogen can be reacted with a metal(I) cyanide. such as
`cuprous cyanide to give a corresponding carbonitrile derivative, which can then be converted to
`compounds of formula (I). eg the carboxylic acid via hydrolysis.
`Those intermediates that are novel form an important further aspect of the present invention.
`(h) Interconversion of compounds of the formula (I) is possible, e.g., by hydrolysis of esters, amides
`and by isomerization about the multiple bonds when such bondsare presentor by selective reduction of
`multiple bonds when such bonds are present.
`The compounds of this invention having antiallergic activity may be used for the same indications as
`clinically used antiasthmatic compounds, namely to help to control bronchoconstriction or brochospasm
`characteristic of allergic asthma and exercise induced asthma and the symptomsof bronchoconstriction and
`bronchospasm resulting from acute or chronic bronchitis. The compounds are believed to inhibit the release
`of autacoids (i.e. histamine, serotonin and the like) from mast cells and to inhibit directly the antigen-induced
`production of histamine. Thus, they may be classified as mastcell stabilizers with antihistaminic action.
`The compounds of this invention having antihistamine activity may be used for the same indications as
`clinically used antihistamines, namely to relieve detrimental symptoms (caused by histamine release) of nasal
`stuffiness due to colds and vasomotorrhinitis and for the symptomatic controlof allergic conditions including
`nasalallergy, perennial rhinitis, urticaria, angioneurotic oedema,allergic conjunctivitis, food allergy, drug and
`serum reactions, insect bites and stings and desensitizing reactions. The compound mayalso be usedin
`conditions responsive to its antipruritic activity including allergic dermatoses, neurodermatitis, anogenital
`pruritus, and pruritus of non-specific origin such as eczema, and of specific cause such as chickenpox,
`photosensitivity and sunburn. The present invention therefore provides a method for the symptomatic
`treatment ofallergic conditions by the administration of an effective amount of a compoundof formula(I). The
`present invention also provides a method for the antagonism of endogenously released histamine by the
`administration of an effective amount of a compound of formula (I). The compounds of formula (I) are
`substantially free from sedative effects.
`The amountof active compound, /e, a compound of formula (I) required for use in the above conditions will
`vary with the compound chosen, the route of administration and the condition and mammal undergoing
`treatment, and is ultimately at the discretion of the physician. A suitable oral dose of the active compoundfor a
`mammalis in the range of from 0.003 to 1.0 mg per kitogram body weight per day; preferably from 0.04 to 0.24
`mg/kg. For examplea typical dose for a human recipient of compound (1}, (Z)-11-(3-(dimethylamino)propyli-
`dene)-6,11-dihydrodibenz[b, ejoxepin-2-carboxylic acid, as the hydrogen chloride salt (see Example 7 and
`Table 1, vide infra) is between 0.03 and 0.1 mg/kg body weight per day.
`The desired daily dose is preferably presented as from one to six sub- doses administered at appropriate
`intervals throughout the day as needed. Where three subdoses of compoundsof formula (I) are employed,
`eachwill preferablylie in the range of from 0.014 to 0.08 mg/kg body weight: for example, a typical sub-doseof
`such a compound for a human recipient is between 1 and 20 mg, for example 4 or 8 mg.
`it is
`While it is possible for a compound of formula (l} to be administered alone as the raw chemical,
`preferable to present the compoundof formula (|) as a pharmaceutical formulation. Thus, the presentinvention
`also provides pharmaceutical formulations, both for veterinary and for human medical use, which comprise a
`compound of formula (1)
`together with one or more pharmaceutically acceptable carriers therefor and
`optionally any other therapeutic ingredients. For example, the active compound may be formulated with a
`sympathomimetic agent such as the decongestant pseudoephedrine, an antitussive such as codeine, an
`analgesic, an antiinflammatory, an antipyretic, or an expectorant. The carrier(s) must be pharmaceutically
`acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious
`to the recipient thereof.
`The formulations include those suitable for oral, rectal, topical, nasal, ophthalmic or parenteral (including
`subcutaneous, intramuscular and intravenous) administration.
`The formulations may conveniently be presented in unit dosage form and may be prepared by any of the
`methodswell knownin the art of pharmacy. All methodsinclude the step of bringing the active compoundinto
`association with a carrier which constitutes one or more accessory ingredients. In general, the formulations
`are prepared by uniformly andintimately bringing the active compoundinto association with a liquid carrier or a
`finely divided solid carrier or both andthen, if necessary, shaping the productinto desired formulations.
`Formulations of the present invention suitable for oral administration may be presented as discrete units
`such as capsules. cachets, tablets or lozenges, each containing a predetermined amount of the active
`compound (defined herein as a compoundof formula (I}); as a powder or granules; or a suspension in an
`aqueousliquid or nonaqueousliquid such as a syrup, andelixir, an emulsion or a draught. A tablet may be
`made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets
`may be prepared by compressing in a suitable machine,with the active compoundbeingin a free-flowing form
`such as a powderor granules which is optionally mixed with a binder, disintegrant, lubricant, inert diluent,
`surface active agent or dispersing agent. Molded tablets comprised of a mixture of the powdered active
`compound with any suitable carrier may be made by molding in a suitable machine.
`A syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar for
`example sucrose to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may
`
`10
`
`15
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 5
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 5
`
`
`
`0 214779
`
`include flavourings, an agent to retard crystallization of the sugar or an agentto increase the solubility of any
`other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, and suitable preservatives.
`Formulations for recta! administration may be presented as a suppository with a usual carrier such as cocoa
`butter, or hydrogenated fats or hydrogenated fatty carboxylic acids.
`Formulations suitable for parenteral administration conveniently comprisea sterile aqueous preparation of
`the active compound whichis preferably isotonic with the blood of the recipient.
`Nasal spray formulations comprise purified aqueous solutions of the active compound with preservative
`agents and isotonic agents. Such formulations are adjusted to a pH and isotonic state compatible with the
`nasal mucous membranes.
`Ophthalmic formulations are prepared by a similar method to the nasal spray except that the pH and isotonic
`factors are adjusted to match that of the eye.
`Topical formulations comprise the active compound dissolved or suspended in one or more media such as
`mineral oil, petroleum, polyhydroxy alcohols or other bases used for topical pharmaceutical formulations. The
`addition of other accessory ingredients, vide infra, may be desirable.
`In addition to the aforementioned ingredients, the formulations of this invention mayfurther include one or
`more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, disintegrants,
`surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
`The present invention also provides the first use of the compounds of formula (I)
`in medicine.
`The following Examples are provided by the wayofillustration of the present invention and should in no way
`be construed asa limitation thereof. All temperatures indicated are in degrees Celsius
`
`Example :1.(E)/(Z)-11-(3-Dimethylamino)propylidene)-6, 11-dihydro-dibenz[b,e]oxepin-2-carboxylic acid
`
`a)2-Bromo-6,11-dihydrodibenz[b, e]oxepin-11-one
`2-Bromo-8, 11-dihydrodibenz[b,e]oxepin-11-one was prepared as described in US Patent 4,282,365,
`m.p. 132-134°C (Lit. m.p. 136-139°C). pmr (DMSO/de) 6: 8.13 (d, J=2.6 Hz, 1H, H1}, 7.48-7.83 (m, 5H,
`aromatic). 7.07 (d. J=8.8 Hz, 1H, H4), 5.31 (s, 2H, CHaO).
`Analysis: Calcd. for Ci4HgBrOe2: C, 58.16; H, 3.14; Br, 27.64. Found: C, 58.20; H, 3.18; Br, 27.73.
`
`b)(£)/(Z)-3-(2-Bromo-6,11-dihydrodibenz[b,e]oxepin-1 1-ylidene)-N,N-dimethylpropylamine
`Anhydrous 3-(dimethylamino)propyltriphenylphosphonium bromide hydrobromide (39.4 g., 0.08 mole) was
`suspended in 450 mL of dry tetrahydrofuran and 100 mL of a solution of n-butyllithium in hexane (1.6 M) was
`added dropwise at 0°C under a nitrogen atmosphere during a 30 minute period. After an additional 10 minutes,
`2-bromo-6, 11-dihydrodibenz[b, e]oxepin-11-one (16.8 g., 0.06 mole) in 150 mL dry tetrahydrofuran was added
`slowly to the deep red solution and the reaction mixture was then refluxed for 18 hours. The reaction mixture
`was poured onto ice-water, and the mixture was extracted with diethyl ether. The ether layer was concentrated
`under reduced pressure and the residue was suspendedin water and then acidified with 6N hydrochloric acid.
`The acidic aqueous layer was washed with hexanes and then was concentrated to give a gummyresidue. The
`residue was crystallized from ethyl acetate/methanol to provide 5.3 g. of pure Z-isomer as its hydrochloride
`salt, m.p. 201-204°C. The mother liquor was chromatographed on a silica gel column (Waters Associates
`-Prep. 500) with ethyl acetate/methanol(8:2) to give an additional 2.55 g. of pure Z-isomer as the hydrochloride
`salt and 2.79 g. of E-isomer as its hydrochloride salt, m.p. 230-233" C. pmr (Z-isomer) (DMSO/dg) 8: 7.25-7.44
`(m, 6H, aromatic). 6.81 (degenerate d, J=9.1 Hz, 1H, Ha), 5.72 (t, J=7.1 Hz, 1H, CH=). 5.22 (s, 2H, CH20),
`3.18 (m, 2H, NCHa2), 2.70 (m, 2H, CHa), 2.66 (s, 6H, NMe2). pmr (E-isomer) (DMSO/d6) 3: 7.23-7.50 (m, 6H,
`aromatic), 6.70 (d. J=8.6 Hz, 1H, H4), 6.10 (t, J=7.2 Hz, 1H, CH=) 5.15 (brs, 2H, CH20)}, 3.07 (m. 2H, NCHa),
`2.65 (s, 6H, NMez), 2.50 (m overlap with DMSO, 2H, CHa).
`
`c(Z)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydrodibenz[b,e]oxepin-2-carboxylic acid (Compound 1}
`A solution of n-butyl lithium in hexane (1.6 M, 3.5 mL) was added dropwise to a solution of 1.8 g. pure
`(Z)-3-(2-bromo-6, 11-dihydrodibenz[b,e]oxepin-11-ylidene)-N,N-dimethylpropylamine in
`100 mL of dry
`tetrahydrofuran at -70°C under a nitrogen atmosphere. After the yellowish-orange solution was stirred at
`-70°C for 10 minutes, gaseous carbon dioxide was bubbled through the reaction medium to give a pale yellow
`solution. The solution was allowed to warm gradually to room temperature and was then concentrated under
`reduced pressure. The foamy residue was dissolved in water, and the mixture was neutralized with 1N
`hydrochloric acid and then extracted with chloroform. Concentration of the chloroform and recrystallization of
`the residue from water gave 0.5 g. pure Z-2-carboxylic acid, m.p. 121-123°C. pmr (CDCl3) 6: 7.87 (d, JS 1 Hz,
`1H, Hi). 7.81 (dd, J=7.8, 2.2 Hz, 1H, H3), 7.25-7.28 (m, 4H, aromatic), 6.82 (degenerate d, J =8.8 Hz, 1H, Ha),
`6.45 (br s, 1H, CO2H), 5.50 (m, 1H. CH=), 5.20 (br s, 2H, CH20), 2.92 (m, 4H, NCH2CHp), 2.66 (s, 6H, NMez2).
`Analysis: Calcd. for CaaH21NO390.55 HeO: C, 72.07; H, 6.68; N, 4.20. Found: C, 72.07; H, 6.69; N, 4.18.
`
`d)(E)-11-(3-(Dimethylamino)propylidine)-6, 11-dihydrodibenz[b,e]oxepin-2-carboxylic acid (Compound 2).
`Pure (E)-3-(2-bromo-6, 11-dihydrodibenz[b,eJoxepin-11-ylidene)-N.N-dimethylpropylamine (1.55 g.. 4.3
`mmole), was treated under nitrogen in cold (-70° C) tetrahydrofuran (100 mL) with 4.4 mmole of n-butyllithium
`in hexane followed by gaseous carbon dioxide as described for the Z-isomer (Step C).
`Isolation of the (E)-2-carboxylic acid was achieved by through chromatographyof the crude product on a
`
`10
`
`15
`
`20
`
`25
`
`30
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 6
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 6
`
`
`
`0 214779
`
`(containing 0.19%
`in water
`reverse phase C18 semipreparative column eluted with 20% methanol
`triethylamine). Recrystallization of the solid product from water afforded 0.012 g of pure E-2-carboxylic acid,
`m.p. > 200°C (decomp.). pmr (CDCl3) 8: 7.85 (cd, J=2.0 Hz, 1H, H1), 7.06-7.78 (m, 5H, aromatic), 6.47 (d,
`J=8.5 Hz, 1H, Ha), 6.28 (t, J=4.2 Hz. 1H, CH=), 5.85 (m, 1H, ArCH), 4.70 (m. 1H, ArCH), 2.43 (m, 4H,
`NCH2CH2}, 2.28 (s, 6H. NMez2).
`Analysis: Calcd. for CagH21NOQ3e0.50 H20: C, 72.27; H, 6.67; N, 4.21. Found: C. 72.15: H, 6.46: N, 4.22.
`
`Example 2(£)/(2)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydro-dibenz[b,e]oxepin-3-carboxylic acid
`
`a) Methyl 2-(3-bromophenoxymethy!)benzoate
`To a mixture of 3-bromophenol(60 g. 0.35 mole) and potassium carbonate (25 g, 0.18 mole) in 250 mL of
`N.N-dimethylformamide was added methyl a-bromo-2-toluate (65 g, 0.28 mole). The reaction mixture was
`Stirred at room temperature for 18 hours, then heated on a steam bath for 3 hours. The mixture was poured
`into ice-water, and the solids were collected byfiltration and washed with water to give the crude product.
`Analytical sample was obtained by recrystallization from methylene chloride/hexanes, m.p. 84-85°C. pmr
`(COCl3) 5: 8.0 (m, 1H. He), 6.93-7.69 (m, 7H, aromatic H), 5.47 (s, 2H, ArCH20), 3.89 (s, 3H, CO2CHs).
`Analysis: Caled. for C1sHi3 BrO3: C, 56.09; H, 4.08; Br, 24.88. Found: C, 56.20; H, 4.12; Br, 24.77.
`
`b) 2-(3-bromophenoxy)methylbenzoic acid
`Methyl 2-(3-bromophenoxy)methylbenzoate (34 g) was refluxed in a mixture of 100 mL of 10% sodium
`hydroxide and 200 mL of methanol for 3 hours. The reaction mixture was concentrated under reduced
`pressure and water was added to the residue. The mixture was then acidified with concentrated hydrochloric
`acid. Extracting the acidic solution with ethyl acetate and then concentration of the organic layer gave the
`2-(3-bromophenoxy)methyl benzoic acid (35 g) m.p. 158-159°C. pmr (CDCL3) 5: 8.10 (m, 1H, H6), 6.84-7.74
`(m, 7H, aromatic H), 6.16 (br s, 1H, COzH), 5.49 (s, 2H, ArCH20).
`Analysis: Calcd. for C14H11BrO3: C. 54.74; H, 3.61; Br, 26.02. Found: C, 54.65: H, 3.61; Br, 26.08.
`
`15
`
`28
`
`c) 3-Bromo-6. 11-dihydrodibenz[b,e]oxepin-11-one
`in 100 mL of trifluoroacetic
`A suspension of 2-(3-bromophenoxymethyl)benzoate (35 g, 0.11 mole)
`anhydride containing 20 drops of boron trifluoride-ether complex was refluxed for 4 hours. The mixture was
`pouredinto ice-water and then extracted with diethyl ether. Concentration of ether solution under reduced
`pressure and chromatography of the residue onasilica gel column (Waters Associates. Prep 500) with
`hexane/methylene chloride (70:30) gave the pure product (14 g). m.p. 110-112°C. pmr (CDCL3) 8: 8.10 (d.
`J=9.1 Hz, 1H, H1), 7.90 (dd, J=1.4, 7.6 Hz, 1H, Hio) 7.57 (dt, J = 1.4, 7.4, 7.4 Hz, 1H H8). 7.48 (dt, J= 1.4.7.6.
`7.6 Hz, 1H, H9), 7.36 (dd, J=1.3, 7.3 Hz, 1H, H7), 7.27 (d,J= 1.8 Hz, 1H, Ha), 7.24 (dd, J= 1.8. 9.1 Hz. 1H. He).
`§.18 (s, 2H, ArCH20).
`Analysis: Calcd. for Ci4HgBrOe2: C, 58.16; H, 3.14; Br, 27.64. Found: C, 58.13; H, 3.19: Br, 27.72.
`
`d)(E)/(Z)-3-(3-Bromo-6,11-dihydrodibenz[b, eloxepin-1 1-ylidene)-N,N-dimethylpropylamine
`Anhydrous 3-(dimethylamino)propyltriphenylphosphonium bromide hydrobromide (24.5 g. 48.0 mmole), 96
`mmole of n-butyl lithium in hexane, and 3-bromo-6, 11-dihydrodibenz[b,e]oxepin-11-one (10 g, 34.6 mmole)
`were reacted in 580 mL dry tetrahydrofuran by the procedure of Example |, step b. This provided an
`(E)/(Z)-(1:3) isomeric mixture of bromoamines (6.0 g). Recrystallization of half of the mixtures (3.0 g) from
`ethyl acetate gave 1.45 g of Z-isomer of 293% stereoisomeric purity (assayed by ‘H-NMR) as a white solid.
`pmr (CDCl3) 5: 7.23-7.31 (m, 4H, aromatic H), 6.92-7.05 (m, 3H, aromatic H), 5.91 (t, 1H, CH=, 7% E-isomer),
`5.60 (t, 1H, CH= , 930%Z-isomer) 5.15 (very br s, 2H, ArCH20), 3.12 (m, 2H. CHa), 2.99 (m, 2H, NCH). 2.78 (s,
`6H, NMeze, 93% Z-isomer), 2.71 (s, 6H, NMé2, 3% E-isomer).
`Analysis: Caled. for CigH2oBrNOe1.0 HCI: C, 57.81; H, 5.36; N, 3.55. Found: C, 57.62: H, 5.33: N. 3.54.
`
`4
`
`e) (E)/(Z)-11-(3-(Dimethylamino)propylidene)-6, 11-dihydrodibenz[b, eJoxepin-3-carboxylic acid (Compounds
`3/4)
`An isomeric mixture E/Z (1:3) of 3-(3-bromo-6, 11-dihydrodibenz[b,e]-11-ylidene]-N,N-dimethylpropylamine
`(3.0 g, 8.5 mmole)in 150 mL dry tetrahydrofuran at -70° C was reacted with 9.4 mmole n-butyllithium in hexane
`followed by gaseous carbon dioxide by the procedure of Example 1, step c, to provide the corresponding
`carboxylic acids as an E/Z (1:3) sterecisomeric mixture. The mixture was chromatographed on a reverse
`phase PRP-1 semi-preparative column with water/acetonitrile (87:13) to provide 0.08 g of E-isomer(lyophilized
`powder} and 0.50 g of Z-isomer(lyophilized powder). pmr (E-isomer) (CDCl3/TFA)5: 7.85 (dd, J =8.0, 1.7 Hz,
`1H, Ha) 7.50 (d, J = 1.7 Hz, 1H, Ha), 7.32-7.43 (m, 4H, aromatic H), 7.16 (m, 1H, H2), 5.99 (t, 1H, CH=), 5.50 (brs,
`1H, ArCHO), 4.85 (br s. 1H, ArCHQ), 3.25 (q, 2H, CHa), 2.86 (s, 3H, NMe), 2.85 (s, 3H, NMe), 2.70 (q, 2H. NCHa).
`pmr (Z-isomer) (CDCL3/TFA) 8: 7.26 (m, 2H, H2 and Ha), 7.24-7.36 (m, 4H, aromatic H), 7.16 (m, 1H, Hy), 5.71
`(t, 1H, CH=). 5.20 (very br s, 2H, ArCH20), 3.32 (q, 2H, CHa), 2.91 (s, 3H, NMe), 2.90 (s, 3H, NMe), 2.89 (m, 2H,
`NCHo).
`Analysis: Calcd. for C2oH2iNO3e0.5 HCle0.2 H20: C, 69.58: H. 6.39; N, 4.06. Found (E-isomer): C, 69.64: H,
`6.25: N, 4.03. Caled. for CogH21NOg00.25 H20: C, 73.26; H, 6.61; N, 4.27, Found (Z-isomer): C, 73.20: H, 6.60;
`N, 4.20.
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 7
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1033, Page 7
`
`
`
`0214779
`
`Example 3:(E/(Z)-(11-(3-Dimethylamino)propylidene)-6,11-dihydrodibenz[b, e]oxepin-8-carboxylic acid
`
`a)8-Bromo-6.11-dihydrodibenz[b, eJoxepin-11-one
`Phenol (8 g. 85 mmole) and potassium carbonate (11.7 g, 85 mmole) in 150 mL of N,N-dimethylformamide
`was reacted with methyl 4-bromo-a-bromo-2-toluate (20 g, 65 mmole) by the procedure of Example 2, step a
`and followed with alkaline hydrolysis by the procedure of Example 2. step b to give the crude
`4-bromo-2-phenoxybenzoic acid (13 g) which was used without further purification.
`The crude 4-bromo-(2-phenoxymethyl)benzoic acid (13 g, 42 mmole) was cyclized in 50 mLoftrifluroacetic
`anhydride containing 1 mL of borontrifluorideether complex by the procedure of Example 2, step c. The solid
`was collected byfiltration and washed with water to give 11.9 g of the tricyclic ketone. m.p. 125-126°C. pmr
`(CDCL3) 5: 8.17-8.30 (m, 1H, H1). 6.99-7.86 (m, 6H, aromatic H), 5.14 (s, 2H, ArCH20).
`Analysis: Caled. for C1aHaBrO2: C, 58.16: H, 3.14; Br, 27.64. Found: C, 58.15: H. 3.17; Br. 27.73.
`
`b)(E)/(Z)-3-(8-Bromo-6,1 1-dihydrodibenz[b.e]oxepin-11-ylidene)-N,N-dimethylpropylamine
`Anhydrous 3-(dimethylamino) propyltriphenylphosphonium bromide hydrobromide (24.5 g, 48 mmole), 96
`mmole of n-butyl lithium in hexane, and 8-bromo-6, 11-dihydrodibenz[b,e]oxepin-11-one (10 g, 34.6 mmole)
`were reacted in 580 mL dry tetrahydrofuran by the procedure of Example |, step b. This provided an E/Z (1:3.5)
`isomeric mixture of bromoamines. Recrystallization of the mixture from diethyl ether gave 0.17 g of Z-isomer
`and 1.8 g of an E/Z (1:4) (assayed by HPLC on C18) isomeric mixture which was used in the next step without
`further purification. pmr (Z-isomer) (CDCl3) 5: 7.38-7.44 (m, 2H, H7 and Hg); 7.13-7.18 (m, 3H, aromatic H);
`6.84-6.93 (m, 2H, H2 and Ha); 5.70 (t. 1H, CH=); 5.15 (brs, 2H, ArCH20); 2.55 (q, 2H, CHa); 2.43 (t, 2H, NCHa);
`2.22 (s, 6H. NMeg).
`Analysis: Calcd. for Ci1gH2oBrNO: C, 63.70; H, 5.63; N, 3.91. Found (Z-isomer): C, 63.85: H, 5.65; N, 3.92.
`
`G)(E)/(Z}-11-(3-(Dimethylamino) propylidene)-6,1 1-dihydrodibenz[b,e]oxepin-8-carboxylic acid (Compounds
`5/6).
`An isomeric mixture E/Z (1:4) of 3-(8-bromo-6, 11-dihydrodibenz[b,e]-11-ylidene)-N,N-dimethylpropylami